EUVIMEDEUVIMED entdecken
Crossref

MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells

Nao Hondo, Masato Kitazawa, Makoto Koyama, Satoshi Nakamura, Shigeo Tokumaru, Satoru Miyazaki, Masahiro Kataoka, Kai Seharada, Yuji Soejima

Cancer Letters · 2023

DOI: 10.1016/j.canlet.2023.216264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Nao Hondo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School o…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Colorectal Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Kirsten rat sarcoma (KRAS) oncogene was "undruggable" until sotorasib, a KRASG12C selective inhibitor, was developed with promising efficacy. However, inhibition of mutant KRAS in colorectal cancer cells (CRC) is ineffective due to feedback activation of MEK/ERK downstream of KRAS. In this study, we screened for combination therapies of simultaneous inhibition to overcome sotorasib resistance using our previously developed Mix Culture Assay. We evaluated whether there was an additive effect of sotorasib administered alone and in combination with two or three drugs: trametinib, a MEK inhibitor, and cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody. The MAPK pathway was reactivated in KRASG12C-mutated cell lines treated with sotorasib alone. Treatment with KRAS and MEK inhibitors suppressed the reactivation of the MAPK pathway, but upregulated EGFR expression. However, the addition of cetuximab to this combination suppressed EGFR reactivation. This three-drug combination therapy resulted in significant growth inhibition in vitro and in vivo. Our data suggest that reactive feedback may play a key role in the resistance signal in CRC. Simultaneously inhibiting KRAS, MEK, and EGFR is a potentially promising strategy for patients with KRASG12C-mutated CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins p21(ras)Colorectal NeoplasmsHumansCetuximabCell Line, TumorProtein Kinase InhibitorsMitogen-Activated Protein Kinase KinasesMutationPiperazinesPyridinesPyrimidines

Stichwörter der Autor:innen

CetuximabColorectal cancerG12CKristen rat sarcoma 2 viral oncogene homologSotorasibTrametinib

Substanzen

CetuximabProto-Oncogene Proteins p21(ras)Protein Kinase InhibitorsMitogen-Activated Protein Kinase KinasessotorasibPiperazinesPyridinesPyrimidines

Autor:innen und Institutionen

  • Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan.
  • Division of Gastroenterological, Hepato-Biliary-Pancreatic, Transplantation and Pediatric Surgery, Department of Surgery, Shinshu University School of Medicine, Matsumoto, Japan. Electronic address: kita118@shinshu-u.ac…

Zitieren

APA

Hondo, N., Kitazawa, M., Koyama, M., Nakamura, S., Tokumaru, S., Miyazaki, S., Kataoka, M., Seharada, K., & Soejima, Y. (2023). MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216264

Vancouver

Hondo N, Kitazawa M, Koyama M, Nakamura S, Tokumaru S, Miyazaki S, et al. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216264

BibTeX
@article{Hondo2023,
  author = {Hondo, Nao and Kitazawa, Masato and Koyama, Makoto and Nakamura, Satoshi and Tokumaru, Shigeo and Miyazaki, Satoru and Kataoka, Masahiro and Seharada, Kai and Soejima, Yuji},
  title = {MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells},
  journal = {Cancer Letters},
  year = {2023},
  doi = {10.1016/j.canlet.2023.216264}
}
Kostenlos starten →